Nuclear stress tests are among the safest procedures in cardiology, with serious complications like heart attack or death occurring extremely rarely. That does not mean they carry zero risk. The test involves both a small radiation dose from the injected tracer and a deliberate provocation of the heart, either through exercise or a drug that mimics exercise. Most people walk away with nothing worse than a flushed face or a brief headache, but the specific risks depend on which tracer is used, how the heart is stressed, and whether you have certain lung or kidney conditions that change the equation.
What Happens During the Test and Where Risk Enters
A nuclear stress test, formally called myocardial perfusion imaging, works in two stages. First, a small amount of radioactive tracer is injected into a vein. Then your heart is made to work harder, either by walking on a treadmill or by receiving a drug that dilates the blood vessels around the heart the way exercise would. A specialized camera captures how the tracer distributes through your heart muscle. Areas that get less blood flow light up differently, revealing blockages or damage.
Risk shows up at both stages. The tracer delivers a dose of radiation, and like any radiation exposure, that carries a theoretical long-term cancer risk. The stress portion, whether physical or pharmacological, temporarily pushes the cardiovascular system harder than normal, which can trigger arrhythmias, drops in blood pressure, or chest pain. Both of these risks are real, but neither is large for the typical patient being referred for the test.
How Much Radiation You Actually Receive
The radiation dose from a nuclear stress test varies widely depending on which tracer the lab uses. Modern technetium-99m protocols deliver an average effective dose of about 12 mSv, while older thallium-201 protocols roughly double that to around 26 mSv.1PubMed Central. Reducing Radiation Exposure from Nuclear Myocardial Perfusion Imaging: Time to Act is Now For context, natural background radiation from the environment gives you about 3 mSv per year. So a single technetium-based scan is roughly equivalent to about four years of background radiation delivered all at once, and a thallium scan is closer to eight or nine years’ worth.
The practical question is whether that dose translates into a meaningful cancer risk. A large modeling study estimated that the cancer risk from a scan performed at age 50 ranged from about 2 additional cancers per 10,000 scans for a low-dose PET ammonia-13 test, up to 25 per 10,000 for a dual-isotope scan combining thallium and technetium. Across all protocols and ages, the roughly 9 million myocardial perfusion scans performed annually in the United States were projected to result in about 7,400 additional future cancers.2PubMed Central. Myocardial perfusion scans: projected population cancer risks from current levels of use in the U.S Those numbers sound alarming at the population level, but for an individual patient, the risk from a single scan is small, on the order of a fraction of a percent. The risk also drops by about half if the scan is done at age 70 rather than 50, because older patients have fewer remaining years in which a radiation-induced cancer could develop.
The choice of tracer matters. Thallium-201 has a half-life of about three days, meaning it lingers in the body much longer than technetium-99m, and guidelines recommend avoiding thallium in patients 70 or younger when a technetium option is available.3JAMA Internal Medicine. Comparison of Radiation Doses and Best-Practice Use for Myocardial Perfusion Imaging in US and Non-US Laboratories In practice, most labs in the U.S. have already moved away from thallium for routine testing, though it has not disappeared entirely.
Side Effects from Pharmacological Stress Agents
If you cannot exercise adequately on a treadmill, you receive a drug that stresses the heart instead. The two main categories are vasodilators, like adenosine and regadenoson, and catecholamine-type agents like dobutamine. Each has a distinct side-effect profile, and the differences are worth knowing about before you arrive for the test.
Regadenoson has become the most commonly used vasodilator in the U.S. because it is given as a single quick injection rather than a prolonged infusion. But it comes with a higher rate of noticeable side effects than older adenosine infusions. One comparison found that roughly 80% of patients receiving regadenoson experienced at least one side effect, compared with about 32% of those receiving adenosine. Shortness of breath was the biggest driver of that gap, occurring in about two-thirds of regadenoson patients versus fewer than one in five adenosine patients. Headache and arrhythmias were also more common with regadenoson.4PubMed. Comparison of the Safety of Adenosine and Regadenoson in Patients Undergoing Outpatient Cardiac Stress Testing A separate study found a somewhat different mix of complaints: flushing was the most common symptom overall, more so with adenosine, while shortness of breath leaned toward regadenoson.5Journal of Cardiovascular Disease Research. Prevalence and significance of electrocardiographic changes and side effect profile of regadenoson compared with adenosine during myocardial perfusion imaging The point is that feeling flushed, short of breath, or headachy during the test is common, expected, and temporary. These symptoms typically resolve within minutes.
Rare but serious reactions do exist. Regadenoson can provoke seizures through activation of adenosine receptors in the brain, though this is uncommon enough to be the subject of individual case reports rather than large-scale statistics.6Journal of Cardiology Cases. A rare complication of a common stress test When side effects are severe or persistent, the antidote aminophylline can be given intravenously to reverse them. In patients with end-stage kidney disease, who tend to metabolize regadenoson more slowly and therefore experience a heavier side-effect burden, aminophylline has been shown effective even when given more than 30 minutes after the stress agent.7PubMed Central. Late Aminophylline Reversal of Regadenoson Stress Testing in Patients with End Stage Renal Disease
Dobutamine, the other major pharmacological stress option, works differently: it directly increases heart rate and contractility rather than dilating blood vessels. In a study of over 1,100 patients, there were no deaths, heart attacks, or sustained dangerous arrhythmias from dobutamine stress. The most common rhythm disturbance was frequent premature ventricular beats, seen in about 15% of patients.8PubMed. Symptoms, adverse effects, and complications associated with dobutamine stress echocardiography. Experience in 1118 patients A larger series of over 3,000 dobutamine studies found that the test had to be stopped early due to side effects in about 8% of patients, and serious complications like sustained ventricular tachycardia or heart attack occurred in less than one-third of one percent. No deaths were recorded in that series either.9PubMed. Evolution of dobutamine echocardiography protocols and indications: safety and side effects in 3,011 studies over 5 years
Exercise Stress and Cardiac Events
If you are doing the treadmill version of the test, the stress comes from your own exertion rather than a drug. This is generally considered the preferred approach when a patient can exercise, because it provides additional diagnostic information like exercise capacity and blood pressure response. But vigorous exercise does carry a small inherent risk of triggering a cardiac event, which is precisely why the test is supervised by a medical team with crash cart and defibrillator at hand.
Research on exercise-related cardiac arrest in patients with known coronary disease has estimated that the transient risk during and immediately after a few minutes of vigorous exertion can be more than 100-fold higher than at rest.10PubMed. Exercise: a risk for sudden death in patients with coronary heart disease That sounds dramatic, but the absolute risk remains low: 100 times a very small number is still a small number. The controlled clinical environment of a stress lab, where the patient is monitored continuously and emergency equipment is immediately available, makes exercise stress testing far safer than unmonitored vigorous exercise in everyday life. The whole premise of the test is to provoke the heart under conditions where any problem can be caught and treated in real time.
Lung Disease and Other High-Risk Situations
The biggest safety concern unique to pharmacological nuclear stress tests involves patients with asthma or chronic obstructive pulmonary disease. Vasodilator agents like adenosine activate receptors that can trigger bronchospasm, meaning the airways tighten and breathing becomes difficult. For years, active or severe asthma was treated as a firm contraindication to vasodilator stress testing.
In practice, the risk has turned out to be more manageable than once feared, especially with newer agents. A study of 50 asthma patients undergoing adenosine-based stress found that 6% experienced severe shortness of breath, but only one patient (2%) developed actual bronchospasm with audible wheezing.11Nuclear Medicine Communications. Pharmacological stress myocardial perfusion scintigraphy: use of a modified adenosine protocol in patients with asthma Another study looking at adenosine in patients with mild asthma or COPD found five cases of bronchospasm that all resolved quickly after the adenosine infusion was stopped, without needing aminophylline rescue.12PubMed. Side effect profile and tolerability of adenosine myocardial perfusion scintigraphy in patients with mild asthma or chronic obstructive pulmonary disease
Regadenoson appears to be somewhat gentler on the airways. A study comparing regadenoson to historical cohorts who received older vasodilators found zero clinical exacerbations of COPD or asthma after regadenoson. Bronchospasm rates were lower with regadenoson than with adenosine in patients with lung disease, though patients did experience more flushing and headache.13PubMed. Hemodynamic response, arrhythmic risk, and overall safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients For patients with severe or unstable asthma, dobutamine stress remains the safer alternative because it does not work through the adenosine receptor pathway that provokes airway narrowing.
How Labs Are Cutting Radiation Doses
One of the most meaningful safety improvements in recent years has been the push to lower the radiation dose per scan. Several strategies are converging to make this possible.
Stress-only protocols skip the rest portion of the scan when the stress images look normal, cutting the tracer dose roughly in half. One study of chest-pain patients using a stress-first approach with a high-efficiency camera achieved an average radiation dose of just about 1 mSv for those who only needed the stress images, and about 2.2 mSv across all patients including those who went on to rest imaging. At one year of follow-up, all patients were alive and none had experienced an acute coronary event.14Journal of Nuclear Medicine. Radiation Dose and Prognosis of Ultra-Low-Dose Stress-First Myocardial Perfusion SPECT in Patients with Chest Pain Using a High-Efficiency Camera That 1 mSv figure is roughly one-third of a year’s worth of background radiation, a far cry from the 12 to 26 mSv of older protocols.
The cameras themselves are improving. Newer solid-state detectors made with cadmium-zinc-telluride are more sensitive than older sodium-iodide crystals, meaning they can produce high-quality images with less tracer and therefore less radiation. Adoption of these cameras varies by lab, but the technology has been shown to dramatically reduce doses without sacrificing diagnostic accuracy.15European Heart Journal – Cardiovascular Imaging. Low dose in nuclear cardiology: state of the art in the era of new cadmium–zinc–telluride cameras Stress-only imaging combined with these newer cameras represents the current best case for minimizing radiation.16PubMed Central. Advances in nuclear cardiac instrumentation with a view towards reduced radiation exposure
When the Test May Not Be Needed at All
One underappreciated safety risk is getting a nuclear stress test when you did not need one in the first place. Every unnecessary test exposes you to radiation and pharmacological stress without any diagnostic benefit. A study of over 400 consecutive nuclear stress test referrals found that while 94% met traditional appropriateness criteria, a radiation-sparing analysis determined that nuclear testing was actually the right modality for only about 18% of those patients. For the rest, a non-nuclear alternative like exercise ECG, stress echocardiography, or cardiac CT could have answered the clinical question without radiation exposure.17Military Medicine. Nuclear Stress Testing Referrals: Time for a Novel Radiation Sparing Approach?
This does not mean nuclear stress tests are being ordered recklessly. Referring physicians are following established guidelines that consider nuclear imaging appropriate. The issue is that “appropriate” under traditional criteria does not always mean “the only option” or even “the best option.” If you have normal resting heart function and can exercise on a treadmill, a simpler exercise ECG or a stress echocardiogram using ultrasound may give your doctor the information needed without any radiation at all. The conversation worth having with your cardiologist is not just whether the nuclear test is appropriate, but whether a radiation-free alternative could work just as well in your specific situation.
Incidental Findings on the Scan
An aspect of nuclear stress testing that most patients do not think about beforehand is the possibility of incidental findings outside the heart. The camera captures a field of view that includes parts of the lungs, liver, thyroid, and other nearby structures. A large retrospective study found that more than half of patients had some kind of extracardiac finding on their scan, with about 14% of those classified as clinically significant. A separate study of PET/CT scans found extracardiac findings in about 17% of patients, with roughly 2% turning out to be malignancies.18European Heart Journal. Imaging Methods and Practice. How to evaluate incidental extracardiac findings on hybrid PET and SPECT/CT imaging?
This is a double-edged sword. Catching an early-stage lung cancer or thyroid nodule by accident is a genuine benefit, and for some patients it is the most consequential part of the test. But incidental findings also lead to follow-up imaging, biopsies, and anxiety about abnormalities that often turn out to be benign. If you are scheduled for a nuclear stress test, it is worth knowing that the results might raise questions unrelated to your heart, and that this is a normal part of how imaging works rather than a sign that something has gone wrong.
What the Test Can Miss
Safety also has a diagnostic dimension. If you undergo a nuclear stress test and receive reassuring results, you want to know how much confidence to place in that reassurance. The answer depends on the type of disease being screened for. A study of dipyridamole stress testing found that the test correctly identified three-vessel coronary artery disease, the most dangerous pattern of blockage, only about 52% of the time. In patients where the right coronary artery or the circumflex artery was the most severely blocked, perfusion defects were absent on the scan in 39% of cases.19Clinical Nuclear Medicine. How Well Does Radionuclide Dipyridamole Stress Testing Detect Three-Vessel Coronary Artery Disease and Ischemia in the Region Supplied by the Most Stenotic Vessel?
This happens because when all three major arteries are similarly narrowed, blood flow may look uniformly reduced across the heart, making the scan appear balanced and deceptively normal. The test is better at detecting single-vessel disease or identifying which territory is at greatest risk when one artery is significantly worse than the others. A normal nuclear stress test is still meaningfully reassuring, especially when combined with clinical information and exercise capacity, but it is not a guarantee that no significant blockage exists. If symptoms persist after a normal result, further evaluation with coronary angiography or CT angiography is sometimes warranted.